Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-006869
Filing Date
2021-05-12
Accepted
2021-05-12 08:23:47
Documents
64
Period of Report
2021-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sbbp-20210331x10q.htm   iXBRL 10-Q 1182078
2 EX-31.1 sbbp-20210331xex31d1.htm EX-31.1 11885
3 EX-31.2 sbbp-20210331xex31d2.htm EX-31.2 11924
4 EX-32.1 sbbp-20210331xex32d1.htm EX-32.1 11519
  Complete submission text file 0001558370-21-006869.txt   5325859

Data Files

Seq Description Document Type Size
5 EX-101.SCH sbbp-20210331.xsd EX-101.SCH 42527
6 EX-101.CAL sbbp-20210331_cal.xml EX-101.CAL 46086
7 EX-101.DEF sbbp-20210331_def.xml EX-101.DEF 125154
8 EX-101.LAB sbbp-20210331_lab.xml EX-101.LAB 420181
9 EX-101.PRE sbbp-20210331_pre.xml EX-101.PRE 292706
10 EXTRACTED XBRL INSTANCE DOCUMENT sbbp-20210331x10q_htm.xml XML 870705
Mailing Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053
Business Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053 (610) 254-9200
Strongbridge Biopharma plc (Filer) CIK: 0001634432 (see all company filings)

EIN.: 981130690 | State of Incorp.: L2
Type: 10-Q | Act: 34 | File No.: 001-37569 | Film No.: 21913565
SIC: 2834 Pharmaceutical Preparations